S. Egyházi Brage

发表

Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer

Mårten Fernö, Srinivas Veerla, Siker Kimbung, 2015, Clinical Cancer Research.

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

J. Hansson, H. Johansson, Rainer Tuominen, 2017, BMC Cancer.

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial

U. Isacsson, R. Kiessling, R. Lewensohn, 2022, Acta oncologica.

Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance

J. Hansson, J. Lehtiö, M. Pernemalm, 2014, British Journal of Cancer.

Laminins 411 and 421 differentially promote tumor cell migration via α6β1 integrin and MCAM (CD146).

R. Kiessling, J. Hansson, M. Patarroyo, 2014, Matrix biology : journal of the International Society for Matrix Biology.

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma

T. Helleday, J. Hansson, V. Höiom, 2020, Cell Death & Differentiation.

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma

V. Höiom, Rainer Tuominen, S. Egyházi Brage, 2022, Cancers.

Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy

H. Helgadottir, S. Rotstein, M. Bergqvist, 2022, Acta oncologica.

BRAF inhibitors in cancer therapy.

S. Egyházi Brage, C. Hertzman Johansson, 2014, Pharmacology & therapeutics.

Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.

S. Puig, N. Hayward, H. Olsson, 2014, The Journal of investigative dermatology.

MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma

J. J. van den Oord, J. Hansson, H. Johansson, 2015, International journal of cancer.

Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma

M. Herlyn, J. Hansson, Gianluca Maddalo, 2020, Cell Death & Disease.

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells

L. Kanter, J. Hansson, J. Lehtiö, 2017, Cell Death and Disease.

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors

Jonathan L. Robinson, J. Nielsen, F. Edfors, 2018, Molecular systems biology.

Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines

J. Hansson, S. Egyházi Brage, M. Frostvik Stolt, 2013, Melanoma research.

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib

D. Grandér, J. Hansson, R. Fernandes, 2020, Melanoma research.

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

S. Kauppinen, H. Olsson, C. Ingvar, 2020, bioRxiv.

Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy

F. Edfors, M. Uhlén, L. Fagerberg, 2021, Cancer Research.

A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma

L. Kanter, J. Hansson, H. Johansson, 2021, Acta oncologica.

High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma

J. Lundeberg, J. Hansson, H. Johansson, 2013, Melanoma research.

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

R. Kiessling, J. Hansson, I. Schultz, 2013, Cancer research.

Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer

H. Johansson, E. Åvall-Lundqvist, J. Carlson, 2013, BMC Clinical Pathology.

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival

M. Fernö, C. Perou, J. Bergh, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status

M. Wilhelm, J. Hansson, V. Höiom, 2019, Cell Death & Disease.

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.

M. Fernö, C. Perou, J. Bergh, 2015 .